INmune Bio
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
225 NE Mizner Blvd Ste 640, Boca Raton, ...Phone Number
(858) 964-3720Website
www.inmunebio.comRevenue
-Stock Symbol
INMBIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About INmune Bio
INmuneBio,Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat cancer (INB03), Mild Alzheimer's disease, Mild Cognitive Impairment and treatment resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.Explore more
INmune Bio Org Chart
CE
Controller & Vice President, Finance
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is INmune Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if INmune Bio has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if INmune Bio had a recent Job posting/layoffs
Earning: See what the market has to say on INmune Bio recently announced quarterly report
INmune Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at INmune Bio
Funding: Get notified immidiatlly once INmune Bio has new funding data
Check out if INmune Bio is spiking on competitors!
Product Launch: Get notified when INmune Bio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined INmune Bio as Masked Content
Find 3 more new buyers
Compare Similar Companies to INmune Bio
Compare insights from companies similar to INmune Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
INmune Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
INmune Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about INmune Bio.
INmune Bio Tech Stack
A closer look at the technologies used by INmune Bio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
reported that Xpro demonstrated safety in early Alzheimer's disease patients, with no significant safety signals other than manageable injection site reactions. The trial provided evidence that targeting neuroinflammation may slow disease progression, with a six-month trial showing benefits using EMAC as a primary cognitive endpoint in patients with high levels of neuroinflammation.
Safety, Medical Research, Pharmaceuticals, Clinical Operations
Project
INmune Bio announced results from the Mindful Trial, a Phase II study evaluating Xpro for early Alzheimer's disease. The trial showed Xpro is safe and prevented cognitive decline in patients with two or more biomarkers of inflammation, although it did not meet primary or secondary endpoints in the modified intent-to-treat population.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals, Clinical Operations, Corporate Strategy
INmune Bio News & Media
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in Alzheimer’s disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro™ (XPro1595, pegipanermin) in patients with mild Alzheimer’s disease characterized by biomaINmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XPro™ (pegipanermin), the company's first-in-class selective soluble TNF inhibitor, for the treatment of early Alzheimer's disease (AD). The designation specifically covers XPro™ for treatment of early Alzheimer's disease encompassing both mINmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadershipINmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Inc. (INMB) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDTCompany ParticipantsDaniel Carlson - Head of Investor RelationsDavid Moss - President,...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INmune Bio
Sign Up For FreeTo access detailed company insights
INmuneBio,Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TN... Read More
